John Solomon, DO
Family Medicine · North Smithfield, RINPI 1861529158
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Pfizer at 25.9% of the total.
Across 127 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$550
- Novo Nordisk$261
- Abbott$165
- GSK$157
- Exact Sciences$144
- Johnson & Johnson$126
- plus $724 from 17 others
What the payments were for
- Food & beverage$2,128100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 39 | $550 |
| Novo Nordisk | 17 | $261 |
| Abbott | 8 | $165 |
| GSK | 10 | $157 |
| Exact Sciences | 6 | $144 |
| Johnson & Johnson | 6 | $126 |
| Corcept Therapeutics | 4 | $87 |
| Sanofi-aventis U.S. LLC | 5 | $81 |
| AbbVie | 3 | $77 |
| Lilly USA, LLC | 5 | $76 |
| Janssen Scientific Affairs, LLC | 3 | $58 |
| Boehringer Ingelheim | 3 | $49 |
| AstraZeneca | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Merck | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Novartis | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$2,128 in reported general payments places this provider in the 80th percentile of 222 family medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $94,609 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $37,467 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $26,657 |
| JardianceEmpagliflozin | 21 | $26,052 |
| Victoza 3-PakLiraglutide | 16 | $16,387 |
| OxycontinOxycodone Hcl | 12 | $16,064 |
| OzempicSemaglutide | 12 | $12,499 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $8,960 |
| Victoza 2-PakLiraglutide | 12 | $6,976 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $6,286 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 19 | $5,443 |
| Atorvastatin Calcium | 397 | $5,155 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $4,154 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $3,781 |
| Duloxetine Hcl | 127 | $3,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $550 | $96,038140 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $81 | $37,46727 claims |
| Boehringer IngelheimJardiance | $49 | $26,05221 claims |
| Novo NordiskOzempic | $261 | $12,49912 claims |
| GSKArexvy | $157 | $5,44319 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $17 | $3,25912 claims |
| AbbVieSynthroid | $77 | $2,68127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 family medicine providers in Rhode Island.
Other family medicine in North Smithfield
- Gina la ProvaCumberland$778K
- Wilfredo Giordano-PerezJohnston$351K
- Martin MinerProvidence$124K
- Frank la FaziaWest Warwick$19K
- Jamiel AmbradWakefield$18K
- Jason AustinJohnston$15K
- Mary SutterPawtucket$13K
- Abdul Rahman Al HoutSmithfield$12K
- Sukanya SomasundarCranston$12K
- Michael HaydenCranston$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.